MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(d)
On April17, 2017, the Board of Directors (the Board) of
MyoKardia, Inc. (the Company) appointed David P. Meeker, M.D. to
the Board as a ClassII director. Dr.Meeker was appointed to a
newly created vacancy on the Board resulting from an increase in
the size of the Board from eight (8)to nine (9)directors.
Dr.Meeker is executive vice president and head of Sanofi Genzyme,
the specialty-care global business unit of Sanofi S.A. (Sanofi)
that focuses on rare diseases, multiple sclerosis, oncology and
immunology, a position he has held since January 2016. He has
also served as a member of Sanofis Executive Committee since
2012. Dr.Meeker joined Genzyme Corporation in 1994 as medical
director and held positions of increasing responsibility,
including vice president, medical affairs, chief operating
officer and ultimately president and chief executive officer when
Genzyme was acquired by Sanofi in 2011. Prior to joining Genzyme,
Dr.Meeker was director of the Pulmonary Critical Care Fellowship
at the Cleveland Clinic and an assistant professor of medicine at
Ohio State University. Dr.Meeker has served as a director of
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, since
November 2015 and as its chairman of the board since April 2017.
Dr.Meeker holds an M.D. degree from the University of Vermont
Medical School and completed the Advanced Management Program at
Harvard Business School in 2000. He will serve on the Boards
science and technology committee.
Upon his appointment to the Board, Dr.Meeker was granted an
option to purchase 22,000 shares of the Companys Common Stock at
an exercise price equal to the closing price of the Companys
common stock on the Nasdaq Global Select Market on April17, 2017,
which will vest in equal monthly installments during the four
years thereafter, subject to Dr.Meekers continued service on the
Board.
Dr.Meeker is an executive officer of Sanofi and currently holds
the position of executive vice president. The Company is a party
to a license and collaboration agreement (the Collaboration
Agreement) entered into in August 2014 with Aventis Inc., a
wholly-owned subsidiary of Sanofi. to the Collaboration
Agreement, in November 2016, Sanofi paid the Company a
$25.0million milestone-based payment in connection with the
Companys submission of an investigational new drug application
for one of its product candidates, MYK-491, to the U.S. Food and
Drug Administration. Additionally, in December 2016, Sanofi
provided the Company with notice of its election to continue the
collaboration through December31, 2018, and in connection with
such election, made an additional payment to the Company of
$45.0million in January 2017.
There are no arrangements or understandings between Dr.Meeker, on
the one hand, and any other persons, on the other hand, to which
Dr.Meeker was selected as a director.
| Item7.01 | Regulation FD Disclosure |
On April18, 2017, the Company issued a press release announcing
the appointment of Dr.Meeker to the Board. A copy of this press
release is furnished as Exhibit 99.1 to this report on Form 8-K.
The information in this Item7.01 and Exhibit 99.1 attached hereto
is intended to be furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act,
except as expressly set forth by specific reference in such
filing.
| Item9.01 | Financial Statements and Exhibits |
(d)Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 | Press Release, dated April18, 2017 |
About MYOKARDIA, INC. (NASDAQ:MYOK)
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM. MYOKARDIA, INC. (NASDAQ:MYOK) Recent Trading Information
MYOKARDIA, INC. (NASDAQ:MYOK) closed its last trading session down -0.15 at 11.40 with 95,908 shares trading hands.